JACC This Week

Latest Episodes:

Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results From a Large European Real-World Registry Oct 27, 2024

Show notes

Author Joerg Hausleiter, MD and Executive Associate Editor Aakriti Gupta, MD, FACC. discuss the TAVR UNLOAD trial, which focused on patients with moderate aortic stenosis (AS) and reduced ejection fraction (HFrEF). The trial found no significant difference in the primary endpoint (composite of mortality, stroke, and hospitalizations) between the TAVR and clinical surveillance groups. However, patients who underwent TAVR showed a significant improvement in quality of life at one year. The conversation highlighted the need for individualized treatment approaches, emphasizing patient selection, while also considering trial limitations, including slow enrollment and study size.

Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-year Outcomes From the TRILUMINATE Randomized Cohort Oct 27, 2024

Show notes

JACC Associate Editor Celina M. Yong, MD, FACC, and JACC: Case Reports Editor in Chief Gilbert H. L. Tang, MD, MSc, MBA, FACC, discuss this paper published in JACC and presented at TCT. TRILUMINATE Pivotal is the first randomized, controlled trial evaluating transcatheter edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR). Adaptive design randomized 572 subjects in the primary or subsequent cohorts. Subjects were elderly with atrial fibrillation and prior HFH. Primary endpoint was met at 1 year with a larger win ratio for T-TEER driven by KCCQ improvement with no significant differences in mortality and tricuspid valve surgery or HFH.

JACC - October 29, 2024 Issue Summary Oct 21, 2024

Show notes

In the October 29, 2024 issue of JACC, Dr. Valentin Fuster explores groundbreaking studies on heart failure treatments, including the impact of sacubitril-valsartan on hypotension, the benefits of intravenous iron for reducing hospitalizations, the prognostic value of platelet FCγRIIA in post-myocardial infarction patients, and innovative AI assessments of environmental factors influencing cardiovascular risk.

Asymptomatic versus symptomatic hypotension with sacubitril/valsartan in heart failure and reduced ejection fraction in PARADIGM-HF Oct 21, 2024

Show notes

In this episode, researchers explore how asymptomatic versus symptomatic hypertension affects heart failure patients on sacubitril valsartan, finding that both types are linked to worse outcomes, but the drug's benefits remain strong, suggesting clinicians should avoid stopping treatment based solely on blood pressure.

The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths. Oct 21, 2024

Show notes

In this episode, Dr. Valentin Fuster reviews the Ironman trial, which studied the effects of intravenous iron on patients with heart failure and iron deficiency. While intravenous iron improved symptoms and reduced recurrent hospitalizations, it did not significantly impact first-time hospitalizations or mortality rates, suggesting the need for further research into its broader clinical benefits.

FcγRIIa: A Marker of Cardiovascular Risk after Myocardial Infarction Oct 21, 2024

Show notes

In this episode, Dr. David J. Schneider research identifies platelet FCγRIIA (PFCG) as a key biomarker for cardiovascular risk post-myocardial infarction. In an 800-patient study, higher PFCG levels were linked to increased risks of myocardial infarction, stroke, and death, indicating its potential for guiding personalized antiplatelet therapy, pending further validation.

AI-Facilitated Assessment of Built Environment Using Neighborhood Satellite Imagery and Cardiovascular Risk Oct 21, 2024

Show notes

In this episode, Dr. Zhuo Chen and his team explore how AI-driven analysis of neighborhood satellite imagery can reveal links between the built environment and cardiovascular risk. Their findings suggest that while AI can predict adverse cardiovascular events, the influence of social determinants, particularly socioeconomic status, plays a critical role in this relationship, underscoring the need for further research into these complex interactions.

Aspirin Hypersensitivity in Patients with Atherosclerotic Cardiovascular Disease Oct 21, 2024

Show notes

In this episode, Dr. Valentin Foster introduces a vital review on aspirin hypersensitivity in patients with atherosclerotic cardiovascular disease, led by Dr. Mattia Galli and Dr. Dominick J. Angiolillo. The discussion spans the history, epidemiology, and mechanisms of aspirin hypersensitivity, alongside strategies for management and practical recommendations for healthcare providers.

Effect of Semaglutide on Cardiac Structure and Function in Patients with Obesity-Related Heart Failure Oct 14, 2024

Show notes

In the October 22, 2024 issue of JACC, a podcast explores the promising benefits of semaglutide, a glucagon-like peptide receptor agonist, in treating obesity-related heart failure. The episode discusses key findings from original research, highlighting how semaglutide improves cardiac structure and function, attenuates adverse remodeling, and showcases the dual mechanisms—both weight-related and independent—behind these effects.

Atrial fibrillation and semaglutide efficacy in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF Program Oct 14, 2024

Show notes

In this episode, Dr. Valentin Foster highlights the October 2024 issue of JACC, which delves into the benefits of semaglutide for obesity-related heart failure with preserved ejection fraction. A key study presented shows that semaglutide significantly improves heart failure symptoms and physical limitations, particularly in patients with a history of atrial fibrillation, underscoring its efficacy beyond mere weight loss.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected

Our TOPPODCAST Picks

Follow Us

Stay Connected

JACC This Week

Related Podcasts

1

2

3

4

5

6